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ABSTRACT
Objectives: To investigate persistence and adherence of
medication treatment in chronic overactive bladder/uri-
nary incontinence (OAB/UI) patients, and to evaluate
OAB/UI-related comorbidity events associated with
persistence.
Methods: Pharmaceutical outcomes research with a
health-care provider perspective was conducted on a Cal-
ifornia Medicaid (Medi-Cal) chronic OAB/UI population.
The primary end point was medication possession ratio
(MPR), which was used to measure reﬁll adherence.
Secondary end points measuring persistence patterns in-
cluded discontinuation of OAB drug therapy (medication-
uncovered interval >30 days) and time to discontinuation
(period from the index date until the ﬁrst discontinua-
tion date). Signiﬁcant factors on nonpersistence were
found by using a Cox Proportional Hazards model.
Factors contributing to nonadherence (MPR < 0.8) and
the relationship between OAB/UI comorbidity events and
persistence were examined by logistic regressions.
Results: Of 2496 eligible patients, 36.9% had only one
OAB/UI prescription. The mean MPR was 0.34 (SD 0.21)
and the median was 0.3, indicating that on average only
about one-third of period of time since medication initi-
ation was covered by the therapy. Only 122 patients
exhibited >80% adherence during the 6-month follow-
up-period. Signiﬁcant predictors of higher persistence
included: white ethnicity, previous hospitalization length,
starting with tolterodine or oxybutynin extended-release,
and previous use of topical drugs or antipsychotics. Nev-
ertheless, previous depression or urinary tract infection
(UTI) diagnosis, polypharmacy, signiﬁcantly increased the
odds of early discontinuation. Treatment discontinuation
increased the risk of UTI diagnosis by 37% in the post-
treatment period (P = 0.03; OR 1.37; 95% CI 1.03–
1.84), but had no signiﬁcant effect on other OAB/UI-
related comorbidities.
Conclusions: For chronic OAB/UI patients identiﬁed in
this study, both persistence and adherence with medica-
tion treatment were suboptimal. These results suggest
that persistence and treatment discontinuation remains
problematic for the OAB/UI population.
Keywords: adherence, compliance, Cox proportional haz-
ard model, logistic regression model, overactive bladder.
Introduction
Urinary incontinence (incontinence, UI) is a condi-
tion referring to any bladder dysfunction of storing
and voiding urine [1,2], and can be transient
(reversible) or chronic. Transient incontinence is
featured with sudden onset, often secondary to
iatrogenic ailments, acute illness, or medication use,
whereas chronic incontinence lasts over a relatively
longer period of time without iatrogenic or acute ill-
ness [3]. Overactive bladder (OAB), deﬁned by the
International Continence Society (ICS) in 1988, is
“characterized by involuntary detrusor contractions
during the ﬁlling phase, which may be spontaneous
or provoked and which the patient cannot com-
pletely suppress [4].” Later, the deﬁnition of OAB
was modiﬁed by ICS in 1999, 2000, and 2001. Spe-
ciﬁcally, OAB is now deﬁned as “denoting urgency,
with or without urge incontinence, usually with fre-
quency and nocturia [5].” Hence, the current OAB
(i.e., OAB syndrome) deﬁnition includes urge syn-
drome and urgency–frequency syndrome [5].
It is estimated that 12 million individuals suffer
from OAB/UI in the United States [6]. This condi-
tion is not as prevalent as asthma (20.3 million) [7],
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but more prevalent than diabetes mellitus among
adults (10.8 million [8]), osteoporosis (10 million
[9]) and Alzheimer’s disease (4 million [10]). The
prevalence of OAB/UI, however, varies in the liter-
ature and this condition is often underdiagnosed
because of the lack of standard or uniﬁed deﬁnitions
being established, embarrassment of patients to
report their symptoms, and/or unawareness of the
onset of this disease. Consequently, up to 50% of all
cases may not be captured in retrospective data [2].
Whether captured or not, OAB/UI exerts a pro-
found effect on a patient’s daily life in both medical
and psychological aspects. The patients have an
increased incidence rate of urinary tract infections
(UTIs), pressure ulcers, urosepsis, perineal rashes,
and falls and fractures [11]. Psychologically, this
condition may bring about anxiety, depression and
isolation to affected patients. They face limitations
in social activities, may gradually lose independ-
ence, and have a lower quality of life. Approxi-
mately $11 billion is spent annually to control
OAB/UI symptoms and treat OAB-related comor-
bidities in the United States [12].
Treatment options for OAB/UI include behavio-
ral therapy, bladder retraining programs, pharma-
cological therapy, and surgery. Because drug
therapy is targeted to speciﬁc abnormalities, the
choice of speciﬁc course of drug therapy is governed
by the type of OAB/UI diagnosed. Currently, major
medications for OAB/UI are composed of ﬂavoxate,
oxybutynin, tolterodine, oxybutynin extended-
release (ER), and tolterodine ER.
Patients’ compliance and persistence during the
course of pharmacological therapy is a major issue
in treating OAB/UI, however, little is known about
the consequences of poor compliance and persist-
ence of OAB/UI treatment. Pharmaceutical out-
comes researchers have found that persistence of
long-term medication is typically low (about 50%)
in a number of chronic disease areas [13–15], and
chronic OAB/UI is likely to be one of them. Patients
may give up in continuing medications or the phy-
sician might decide to stop prescribing a medication
if the side effects or complications of the drug ther-
apy outweigh the known beneﬁts. A Canadian
study (in Quebec) on incontinence drug utilization
patterns revealed low renewal rates of prescriptions
(< 40%) and poor persistence after 6 months
(< 12%) [16]. A study of treatment of urge incon-
tinence in veterans of the United States showed the
majority of patients who received a prescription did
not routinely reﬁll medication over the course of the
study, and less than 30% of the patients were able
to continue on therapy for 1 years [17]. Currently,
there are few published studies on the long-term
persistence with drug therapy among OAB/UI
patients in the United States and the potential ben-
eﬁts of persistence and adherence are less studied
[18,19].
The objectives of the present study include three
components aimed to beneﬁt health-care providers:
1) to investigate persistence pattern and reﬁll adher-
ence among chronic California Medicaid OAB/UI
patients; 2) to build the risk proﬁle of discontinua-
tion and nonadherence for OAB/UI patients; and 3)
to evaluate OAB/UI-related comorbidity events
associated with persistence.
Data and Methods
Data
The study cohort was extracted from a 20% ran-
dom sample of the administrative ﬁles provided by
the California Medicaid program (Medi-Cal) from
January 1999 to April 2002. Medi-Cal is a program
that ﬁnances California residents who have limited
resources and income, with a wide range of health-
care services. All claims data are captured by a com-
puterized database of linked pharmacy, physician,
hospital and nursing home records and encoded to
preserve patient and physician anonymity. Each
record contains information on demographic char-
acteristics, the speciﬁc drug dispensed (NDC codes),
dosage, quantity dispensed, number of days’ supply,
diagnosis (ICD-9 codes), service date and place,
health-care procedures (CPT codes), length of stay,
and eligibility proﬁle. In addition, several variables
are created based on these raw data, index drug
(OAB/UI medication dispensed at the index date;
oxybutynin, tolterodine, oxybutynin ER, and other;
data on tolterodine ER were not available at the
given study period), switch of drug therapy (when a
patient ﬁlled a different brand of OAB/UI drug from
the index drug after index date at the ﬁrst time),
Charlson Comorbidity Index (CCI) [20], outpatient
visits, inpatient hospitalizations, and emergency
room visits and the following outcome-related var-
iables. In this study, three different CCI’s were cal-
culated. Pre-index CCI was computed by using the
associated disease diagnosis codes or procedure
codes recorded within 6 months before the index
date, not including index date, and index date CCI
was calculated by related codes only on the index
date. In this study, ﬁve OAB/UI-related comorbidi-
ties are considered: obesity, depression, UTI, skin
infection, and fall/fracture. The diagnosis of comor-
bidities before the ﬁrst discontinuation was not
counted to avoid potential endogeneity and more
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robust prediction of comorbidities. For UTI inci-
dence, adjusted incidence rate was used to reﬂect
clinical practice pattern. Since symptoms of OAB in
early stage, acute or chronic, mimic UTI, many phy-
sicians initially diagnose as UTI and later change to
OAB if the symptoms continue. To avoid overesti-
mating the incidence of UTI, those UTI diagnoses
that occurred within 30 days of the OAB diagnosis
were not counted as a UTI.
Patient Identiﬁcation
Chronic OAB/UI patients receiving drug therapy
were identiﬁed as adult patients (age ≥ 18 years)
who 1) were dispensed any OAB/UI medication
during the index period from July 1999 to April
2001 (the date of the ﬁrst OAB/UI prescription was
marked as the index date), and 2a) were diagnosed
with OAB/UI at least twice from January 1999 to
April 2002 (study period), or 2b) ever diagnosed
with OAB/UI after the index date (initial selection
of 3665 patients). These selection criteria were rel-
atively conservative for the given Medi-Cal data set,
as there were 14,563 patients with at least one
OAB/UI diagnosis; 12,528 patients with at least two
diagnoses; 10,861 patients with at least one OAB/
UI prescription; 7158 patients with at least two
prescriptions in the study period. To evaluate the
consequences of OAB/UI drug therapies more accu-
rately, those enrollees dispensed an OAB/UI drug
6 months before the index date (washout period/
preperiod) were excluded (n = 712). A few patients
(n = 16) were excluded because of multiple OAB/UI
prescriptions ﬁlled on the index date. Finally, 441
subjects who were not continuously enrolled in the
whole study period (6-month preperiod and 6-
month follow-up period) were excluded, yielding a
ﬁnal study cohort of 2496 subjects.
Outcome Measures
Persistence. Persistence in the present study was
measured by the length of continuous pharmacolog-
ical treatment. Patients discontinued their treatment
if they failed to reﬁll OAB/UI agents within 30 days
after the expected end date of the previous prescrip-
tion. Time to discontinuation was deﬁned as the
number of days between the index date and the ﬁrst
discontinuation date. Patients who switched from
one brand of OAB/UI drug to another within
30 days were considered persistent on their therapy.
The purpose of allowing a reﬁll gap was to avoid
misclassiﬁed discontinuations when patients
delayed the purchase of their medication by a few
days. Patients who restarted any brand of OAB/UI
drug after their ﬁrst discontinuation by the end of
the postperiod were considered as “restarters” of
medication treatment.
Descriptive analysis for persistence pattern was
carried out on two levels: no discontinuation versus
discontinuation using the entire study population
and a subanalysis of discontinuers with no restart of
drug therapy versus discontinuers with restart of
drug therapy.
Adherence. Adherence is the degree of prescription-
ﬁlling in a given time frame. In a large observational
study, failure to reﬁll is considered the most reliable
objective measure of adherence [21]. A medication
possession ratio (MPR) was used in this study as a
measure of failure to reﬁll, calculated as the sum of
days with supply of any OAB/UI drug prescribed
over the follow-up period divided by the total days
followed up (181 days for the 6-month follow-up
period). If the last prescription ﬁlled in the follow-
up period continued after the end of the follow-up
period, surplus days outside the follow-up period
were not counted in the numerator when MPR was
computed. An alternative way of computing MPR is
to allow a variable window for each patient based
on the last prescription ﬁll in the postperiod. For
example, if the last prescription ﬁll includes 10 sur-
plus days after the end of the 6-month postperiod,
the denominator of the MPR formula becomes
191 days rather than a ﬁxed 181-day window.
Accordingly, the maximum numerator can be up to
191 days. The alternative method showed a slightly
higher MPR than the one used in this study (0.36 vs.
0.34), however, the implied adherence was not sig-
niﬁcantly different (P = 0.605). Hence, MPR based
on 6-month ﬁxed period was used in this study. For
patients simultaneously taking two or more agents
in the same class, the overlapping medication-cov-
ered days were not double counted. Based on each
individual patient’s MPR, the cohort was catego-
rized into two groups: those adherents with drug
therapy (MPR ≥ 0.8) and those not adherent with
drug therapy (MPR < 0.8). To examine the varia-
tion of adherence rate due to different MPR cutoff,
0.5 through 0.9 in addition to 0.8 from the litera-
ture [22–26], were used for a sensitivity analysis on
adherence rate and MPR.
Statistical Analysis
Univariate analyses were used to compare persist-
ence groupings (no discontinuation vs. discontinu-
ation, no restarter discontinuation vs. restarter
discontinuation). The Wilcoxon ranksum test was
used for continuous variables and chi-square test
was used for categorical variables.
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A survival curve describing the crude persistence
pattern of OAB/UI treatment was generated using
the unadjusted Kaplan–Meier method. Patients who
remained on their initial treatment until the end of
the follow-up period were regarded as censored
data, and the length of the follow-up period was
assigned as their survival time. Cox proportional
hazard regression was applied to investigate the
effect of explanatory factors on persistence dura-
tion. Time to discontinuation was modeled as the
dependent variable, and the independent variables
included age, sex, ethnicity, index drug, and other
baseline characteristics such as comorbidity proﬁle,
medication use history, health-care utilization,
length of hospitalization, and the number of drug
classes prescribed. Partial Hazard assumption was
tested by the signiﬁcance of added time dependent
covariates (covariates interacted with logged time to
discontinuation). If any time dependent covariate is
found to be signiﬁcant, it will substitute the original
covariates to capture time varying effects.
Multivariate logistic regression analysis was
implemented to calculate the marginal risk of the
aforementioned factors in the Cox model for non-
adherence (dependent variable), and to examine the
relationship between persistence and clinical out-
comes in terms of incidence of OAB/UI-related
comorbidities.
All analyses were performed using SAS version
9.1 (SAS Institute Inc., Cary, NC, 2003) and statis-
tical signiﬁcance was determined at the level of P
value = 0.05 (signiﬁcance at 10% level was also
provided in the ﬁrst two tables of subgroup com-
parisons only for a better explanation purpose). The
stepwise selection method was used to include can-
didate covariates in the model with a P value equal
to 0.25 as a cutoff point, as recommended by Hos-
mer and Lemeshow [27]. Other levels frequently
used range from 0.15 to 0.25 [27–32].
Results
Patient Population Characteristics
For 2496 patients who met inclusion criteria, the
baseline demographic and clinical characteristics
along with comparisons by persistence groupings
are presented in Table 1 (including no discontinua-
tion vs. discontinuation comparison) and Table 2
Table 1 Baseline demographics and clinical characteristics of study cohort (n = 2496)
No discontinuation Discontinuation P value Overall
N 553 1943 2496
Age (mean, SD) 62.95 (16.79) 63.21 (15.97) 0.76 63.15 (16.14)
Dual eligibility: Medicare + Medicaid n (%) 156 (28.2%) 560 (28.8%) 0.78 716
Male n (%) 138 (25.0%) 396 (20.4%) 0.02 534
Ethnicity <0.01
White n (%) 328 (59.3%) 948 (48.8%) 1276
African American n (%) 44 (8.0%) 167 (8.6%) 211
Hispanic n (%) 19 (3.4%) 98 (5.0%) 117
Asian n (%) 25 (4.5%) 107 (5.5%) 132
Other ethnicities n (%) 137 (24.8%) 621 (32.0%) 758
Drug prescribed on the index date <0.01
Tolterodine 255 (46.1%) 838 (43.1%) 1093
Oxybutynin extended-release 144 (26.0%) 380 (19.6%) 524
Oxybutynin 144 (26.0%) 668 (34.4%) 812
Other OAB drugs 10 (1.8%) 57 (2.9%) 67
CCI for pre-index 6 months (mean, SD) 1.56 (1.68) 1.5 (1.75) 0.17 1.52 (1.73)
CCI on the index date (mean, SD) 0.12 (0.45) 0.09 (0.36) 0.10 0.09 (0.38)
CCI for the whole study period (mean, SD) 1.56 (1.68) 1.5 (1.75) 0.17 1.52 (1.73)
OAB/UI-related comorbidities
Obesity n (%) 22 (4.0%) 44 (2.3%) 0.03 66
Depression n (%) 38 (6.9%) 138 (7.1%) 0.85 176
Urinary tract infection n (%) 87 (15.7%) 375 (19.3%) 0.06 462
Skin infection n (%) 39 (7.1%) 113 (5.8%) 0.28 152
Fall/fracture n (%) 59 (10.7%) 227 (11.7%) 0.51 286
Health-care utilization
Number of drug classes prescribed (mean, SD) 7.28 (3.98) 7.18 (4.08) 0.57 7.20 (4.06)
Physician ofﬁce encounters (mean, SD) 14.21 (15.81) 13.2 (14.08) 0.11 13.43 (14.48)
Any inpatient visit n (%) 133 (24.1%) 375 (19.3%) 0.01 508
Any emergency room visit n (%) 30 (5.4%) 127 (6.5%) 0.34 157
Medication use
Any UTI drug use n (%) 35 (6.3%) 168 (8.6%) 0.08 203
Any topical drug use n (%) 239 (43.2%) 677 (34.8%) 916
Any antidepressant use n (%) 165 (29.8%) 578 (29.7%) 743
Any antipsychotics use n (%) 150 (27.1%) 258 (13.3%) 408
CCI, Charlson Comorbidity Index not including age.
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(including no restarter discontinuation vs. restarter
discontinuation comparison). Twenty percent of the
entire study population (534 of 2496 patients) was
male and more than half of the patients (1276 of
2496 patients) were white. The average age at the
time of index prescription was 63.2 years; and most
patients began treatment with tolterodine (44%,
1093 of 2496 patients) or oxybutynin (33%, 812 of
2496 patients). Only 524 patients (21%) were dis-
pensed oxybutynin ER. The initiation of tolterodine
ER was not observed in this cohort because of the
timing of this study in relation to the approval of
the drug. The no discontinuation and discontinua-
tion subcohorts had similar baseline characteristics
except that the no discontinuation subcohort had
more males (25.0% vs. 20.4%; P = 0.0207), more
whites (ethnic composition comparison: P < 0.01),
more obese patients (P = 0.0267), a higher hospital-
ization rate (P = 0.0144), a higher topical drug use
rate (P < 0.01), and a higher rate of antipsychotics
use (P < 0.01). The discontinuation subcohort had a
lower percentage of patients who initiated oxybu-
tynin ER and a higher percentage of patients who
initiated oxybutynin (index drug comparison:
P < 0.01). In the comparison of no-restarters versus
restarters groups, restarters group had a higher pro-
portion of patients who were eligible for both Med-
icaid and Medicare (P < 0.01), about 4% fewer
male patients (P = 0.088), and 5% higher antide-
pressant use (P = 0.0139).
The mean CCI of patients and OAB/UI-related
comorbidities [33] were not signiﬁcantly different in
no discontinuation versus discontinuation compar-
ison nor in no restarter versus restarter comparison.
Among OAB/UI-related comorbidities, UTI was
most prevalent (18.5%, 462 of 2496), followed by
falls/fractures (11.5%, 286 of 2496), depression
(7.1%, 176 of 2496), skin infections (6.1%, 152 of
2496), and obesity (2.6%, 66 of 2496).
Health-care resources were highly utilized by
patients in the 6-month preperiod. On average,
patients ﬁlled seven classes of drug and had 13 out-
patient visits in this period. About 20% of the
patients were hospitalized at least once and 157
patients (6.3%) had at least one emergency room
visit within this period.
Table 2 Baseline demographic and clinical characteristics of patients discontinued therapy (n = 1943)
Discontinuation*
and no-restart
Discontinuation
and restart† P value
All  
discontinuation
N 1380 563 1943
Age (mean, SD) 62.97 (16.12) 63.8 (15.58) 0.4 63.21 (15.97)
Dual eligibility: Medicare + Medicaid n (%) 374 (27.1%) 186 (33.0%) <0.01 560
Male n (%) 295 (21.4%) 101 (17.9%) 0.09 396
Ethnicity 0.73
White n (%) 678 (49.1%) 270 (48.0%) 948
African American n (%) 116 (8.4%) 51 (9.1%) 167
Hispanic n (%) 70 (5.1%) 28 (5.0%) 98
Asian n (%) 70 (5.1%) 37 (6.6%) 107
Other ethnicities n (%) 445 (32.3%) 176 (31.3%) 621
Drug prescribed on the index date 0.36
Tolterodine 587 (42.5%) 251 (44.6%) 838
Oxybutynin extended-release 274 (19.3%) 106 (18.8%) 380
Oxybutynin 473 (34.3%) 195 (34.6%) 668
Other OAB drugs 46 (3.3%) 11 (2.0%) 57
CCI for pre-index 6 months (mean, SD) 1.49 (1.77) 1.52 (1.71) 0.54 1.5 (1.75)
CCI on the index date (mean, SD) 0.09 (0.38) 0.07 (0.31) 0.30 0.09 (0.36)
CCI for the whole study period (mean, SD) 1.49 (1.77) 1.52 (1.71) 0.55 1.5 (1.75)
OAB/UI-related comorbidities
Obesity n (%) 32 (2.3%) 12 (2.1%) 0.80 44
Depression n (%) 100 (7.3%) 38 (6.75%) 0.70 138
Urinary tract infection n (%) 257 (18.6%) 118 (21.0%) 0.24 375
Skin infection n (%) 81 (5.9%) 32 (5.7%) 0.87 113
Fall/fracture n (%) 156 (11.3%) 71 (12.6%) 0.42 227
Health-care utilization
Number of drug classes prescribed (mean, SD) 7.27 (4.16) 6.97 (3.88) 0.26 7.18 (4.08)
Physician ofﬁce encounters (mean, SD) 13.36 (14.39) 12.82 (13.28) 0.38 13.2 (14.08)
Any inpatient visit n (%) 273 (19.8%) 102 (18.1%) 0.40 375
Any emergency room visit n (%) 92 (6.7%) 35 (6.2%) 0.72 127
Medication use
Any UTI drug use n (%) 120 (8.7%) 48 (8.5%) 0.90 168
Any topical drug use n (%) 467 (33.8%) 210 (37.3%) 0.15 677
Any antidepressant use n (%) 433 (31.4%) 145 (25.8%) <0.01 578
Any antipsychotics use n (%) 181 (13.1%) 77 (13.7%) 0.74 258
*Discontinuation was deﬁned as medication-uncover interval >30 occurred during the 6-month follow-up period.
†Restart was deﬁne as patients ﬁlled any brand of OAB/UI drug after their ﬁrst discontinuation by the end of the 6-month follow-up period.
CCI, Charlson Comorbidity Index not including age.
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Topical drugs were most widely used before
index date among the study population, and the
use of antidepressants was second most common
followed by antipsychotics and UTI drugs. Signiﬁ-
cant difference was shown in the use of topical
drugs and antipsychotics in the both comparisons of
no discontinuation versus discontinuation and no
restarters versus restarters. Interestingly, the no dis-
continuation subcohort also had a higher utilization
rate of topical drugs and antipsychotics than the
discontinuation subcohort. In the discontinuation
subcohort, the no restarter group had a higher rate
of antidepressants use than the restarter group. Per-
haps the high prevalence of skin infection, depres-
sion, and UTI can explain the widespread use of
corresponding drugs (topical drugs, antidepres-
sants, antipsychotics and UTI drugs) observed dur-
ing the wash-out period.
Persistence and Adherence of OAB/UI Treatment for a 
6-Month Follow-up Period
Of 2496 subjects, 920 patients (36.9%) had no reﬁll
after the index prescription during the 6-month fol-
low-up period. There were 1671 patients (66.9%)
unable to remain on their treatment for longer than
90 days, and 1943 patients (77.8%) for longer than
150 days. The median time to discontinuation was
50 days with 25% and 75% quartile of 30 and
131 days, respectively (Fig. 1).
Approximately, 4.8% (121 of 2496) of patients
renewed their prescriptions on time or within the
30-day gap. On average, about one-third of the fol-
low-up period was covered by OAB/UI medications
(mean MPR = 0.35, SD 0.21), and 50% of patients
received pharmacological treatment for less than
60 days cumulatively during the 6-month follow-up
period (median MPR = 0.3, interquartile range =
0.17–0.49).
Sensitivity Analysis on Persistence and Adherence
Considering the fact that more than 20% of
patients remained on drug therapy at the end of the
6-month follow-up period, we extended the follow-
up period from 6 to 12 months to more carefully
examine the degree of variation in persistence.
The comparison between the 6- and 12-month
follow-up period is presented in Table 3. Eighty-one
patients were additionally excluded in 1-year fol-
low-up study because the eligibility of those patients
was changed during the extended 6 months, result-
ing in 2415 patients remaining in 1-year follow-up
study. In this analysis, the rate of discontinuation
was increased to 88.6% (2139 of 2415 patients).
Only 10% of patients continued their pharmacolog-
Figure 1 Kaplan–Meier survival curve of per-
sistence of OAB/UI patients for 12 months.
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Table 3 Persistence and adherence patterns at 6- and 12-month of follow-up, respectively
Following up for 6 months (N1 = 2496) Following up for 12 months (N2 = 2415)*
Discontinuation n (%) 1943 (77.8%) 2139 (88.6%)
Switch n (%)† 303 (12.1%) 474 (19.6%)
MPR (mean, SD) 0.34 (0.21) 0.22 (0.16)
Adherence n (%) 122 (4.9%) 17 (0.7%)
Time to discontinuation (median, Q1, Q3) 50 (30,131) 50 (30,133)
Discontinuation at 30 days n (%) 1066 (42.7%) 1032 (42.7%)
Discontinuation at 90 days n (%) 1671 (67.0%) 1614 (66.8%)
Discontinuation at 150 days n (%) 1943 (77.8%) 1874 (77.6%)
Discontinuation at 270 days n (%) Not available 2084 (86.3%)
*There are a smaller number of patients for the 12-month follow-up because of the additional continuous enrollment required.
†Rates of switching were determined for those receiving a medication on the index date and starting a different brand of medication later in the follow-up period.
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ical treatment for longer than a year. The median
time to discontinuation was 50 days and the quar-
tiles of time to discontinuation were 30 days and
133 days, which were similar to the distribution in
the 6-month follow-up study. The mean MPR, how-
ever, dropped signiﬁcantly to 0.22 and the adher-
ence rate (MPR > 0.8) was merely 0.7%.
To examine the variation of adherence rate due
to different MPR cutoff points, we applied 0.5, 0.6,
0.7, and 0.9, respectively, as a cutoff point in addi-
tion to 0.8. Our ﬁndings suggest that, during 6-
month follow-up period, adherence rates increased
from 5% at 0.8 levels to 20% at 0.5 level, rose up
to 14% at 0.6 levels and 8% at 0.7 levels, but
decreased markedly from 5% at 0.8 levels to 2% at
0.9 levels. This sensitive change of adherence rate
by different MPR cutoff points seems an obstacle to
compare the results of OAB/UI studies on adherence
using different MPR cutoff points.
Determinants of Persistence and Adherence
Figure 2 and Table 4 describe the ﬁnal Cox regres-
sion model selected by the stepwise model selection
method and proportional hazard assumption tests.
The most notable ﬁnding from the Cox regression
model is that the index OAB drug signiﬁcantly
affected persistence. Compared with oxybutynin
(the reference group), the tolterodine group and the
oxybutynin ER group showed a favorable result
for persistence. On the contrary, previous depres-
sion diagnosis, UTI diagnosis, and polypharmacy
increased the hazard rate. Even though this is a ret-
rospective study, the association between UTI diag-
nosis and persistence may suggest that a further
clinical research is needed.
Figure 3 and Table 5 present the result of logistic
regression on adherence, where the stepwise model
selection method was used to select covariates.
Compared with oxybutynin, tolterodine and oxy-
butynin ER showed a higher rate of prescription
renewal whereas the other OAB group was not dif-
ferent from oxybutynin. A previous OAB diagnosis
showed a negative effect on prescription renewal,
which may be resulted by an ineffective OAB drug
therapy.
Comorbidities Associated with Persistence
Urinary tract infection incidence was the only
comorbidity that showed a signiﬁcant relationship
(P < 0.5) with discontinuation of OAB drug therapy
(Table 6; age square term was also included in the
model to capture nonlinearity of age effect on UTI
incidence). Considering other variables selected in
the model by the stepwise method, discontinuation
of OAB drug therapy increased the incidence of UTI
by 37%. Hence, persistence played a positive role to
reduce the incidence of UTI. Compared with oxy-
butynin, tolterodine showed a 24% lower incidence
of UTI, whereas, oxybutynin ER and the other OAB
drug group did not differ from oxybutynin.
Discussion
In the current study assessing long-term persistence
and adherence of OAB/UI drug therapy, we
observed a wide spectrum of persistence patterns
and poor utilization of OAB/UI drugs. In general,
there was a high discontinuation rate, although
more than 10% of patients were persistent over
Figure 2 Cox regression on time to discontinuation during
6 months follow-up (reference index drug = oxybutynin).
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12 months, and a low adherence rate after the ini-
tiation of therapy. The present study documents
persistence and adherence patterns among patients
with chronic OAB/UI in an 1-year time frame,
showing the negative impact of early discontinua-
tion on comorbidities (namely UTI), and suggesting
that, in the population deﬁned for the analysis,
long-term pharmacotherapy of OAB/UI has limited
treatment success because of patients’ suboptimal
medication ﬁlling behavior.
Overactive bladder/urinary incontinence is dra-
matically underdiagnosed by about 50% [2] mainly
because patients reluctantly discuss their symptoms
with physicians unless it becomes very severe.
Hence, based on our patient identiﬁcation criteria,
our study cohort was focused on patients suffering
from a chronic OAB/UI condition with above-
average severity. The low persistence and adherence
observed in the present study may suggest that
compliance among less severe OAB/UI patients is
even worse. The discontinuation rate of our data is
higher than the rates reported in clinical trials of
anti-OAB/UI drugs, in which an elderly population
reported drop-out rates of about 8% because of
adverse effects for tolterodine and oxybutynin ER
Table 4 Cox regression on persistence for 6-month follow-up period
Hazard ratio (HR) P value 95% CI of HR
Male 0.90 0.06 0.80–1.00
White 0.90 0.02 0.82–1.98
Any previous OAB diagnosis 1.10 0.14 0.97–1.26
Previous hospitalization length (in days) 1.00 <0.01 1.00–1.00
Index drug: tolterodine* 0.74 <0.01 0.67–0.81
Any previous topical drug use 0.79 <0.01 0.70–0.89
Multiple drugs used (polypharmacy) 1.26 <0.01 1.09–1.46
Any previous obesity diagnosis 0.84 0.26 0.62–1.14
Any previous depression diagnosis 1.20 0.05 1.00–1.44
Any previous UTI diagnosis† 1.16 0.01 1.04–1.30
CCI on index date 0.90 0.11 0.80–1.02
Any previous OAB-related hospitalization ¥ time to discontinuation 1.03 0.58 0.92–1.17
Index drug: oxybutynin extended-release ¥ time to discontinuation 0.88 <0.01 0.85–0.90
Index drug: other OAB drugs ¥ time to discontinuation 0.99 0.82 0.93–1.06
Any previous antipsychotics use ¥ time to discontinuation 0.85 <0.01 0.83–0.88
*Reference index drug is oxybutynin.
†UTI diagnosis in 30 days before OAB/UI diagnosis was considered as OAB/UI diagnosis and was excluded from this calculation to reﬂect clinical practice pattern.
CI, conﬁdence interval; CCI, Charlson Comorbidity Index not including age.
Figure 3 Logistic regression on adherence during 6 months of fol-
low-up (reference index drug = oxybutynin).
Any previous OAB
diagnosis
Previous
hospitalization
length (in days)
Index drug:
tolterodine
Index drug:
Oxybutynin
extended-release
Any previous UTI
drug use
Any previous 
topical drug use
CCI on index date
Odds ratio 0.0 0.5 1.0 1.5 2.0 2.5 3.0 4.03.5
Table 5 logistic regression on adherence for 6-month follow-up period
Odds ratio (OR) P value 95% CI of OR
Any previous OAB diagnosis 0.63 0.05 0.40–1.00
Previous all hospitalization length (in days) 1.01 0.06 1.00–1.01
Index drug: tolterodine* 1.75 0.02 1.10–2.78
Index drug: oxybutynin extended-release* 2.25 <0.01 1.36–3.75
Any previous UTI drug use 0.35 0.04 0.13–0.95
Any previous topical drug use 1.37 0.09 0.95–1.99
CCI on index date 1.26 0.24 0.85–1.86
*Reference index drug is oxybutynin.
CI, conﬁdence interval; CCI, Charlson Comorbidity Index not including age.
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[34–37], and one reported a withdrawal rate for tol-
terodine of 15% [38]; whereas the drop-out rate
due to adverse effects for oxybutynin could be as
high as 17% [34].
The study of persistence and adherence would
beneﬁt from patient-reported side effect data. Nev-
ertheless, this was not possible using retrospective
data. There is evidence suggesting that OAB
patients who continue their medication have greater
improvement in relevant symptoms and utilize
fewer resources [18]. Nevertheless, patients are
often unable to be compliant and persistent with
their therapy because of side effects of OAB/UI
drugs [22,39–41], Therefore, better management of
adverse effect of OAB/UI drugs will help to improve
patient’s compliance with treatment.
Few studies have assessed the clinical beneﬁt
from persistence with OAB/UI drug therapy. The
present study demonstrated the adverse effect of
therapy discontinuation in that the risk of UTI was
37% higher in those that discontinued drug therapy.
This further supports continuous therapy among
chronic OAB/UI patients. Nevertheless, because
Medi-Cal enrollees are not completely representa-
tive of the general population, additional studies in
more general population are necessary to fully
assess the impact of OAB/UI persistence on UTI
incidence.
The gap between prescription ﬁlls was used to
determine discontinuation. In our study, we used
30 days as the permissible gap between prescrip-
tions without classifying a subject as discontinuing
drug therapy. Some other persistence studies used
different gap deﬁnitions, for example, 45 days
[17,22,23]. There is one study deﬁning the gap as a
half of days’ supply of the previous prescription and
changing the gap to 7 days if the prescription was
for 14 days or fewer [16]. Another study deﬁned the
gap as 1.5 times the duration of the index dispen-
sation, or 7 days, whichever was longer [42]. Nev-
ertheless, there is no deﬁnitive evidence suggesting
which gap length is most appropriate to assess per-
sistence among OAB/UI patients.
The value ≥ 0.8 for MPR was used to decide if
the patient was adherent or not in this study.
Nevertheless, no study can demonstrate that 0.8 is a
panacea. Because of the nature of clinical differ-
ences among various therapeutic classes, applying
the same threshold value to determine patient
adherence for different diseases or conditions may
result in an over- or underestimation. Therefore,
there is a clear need for further research to develop
disease-speciﬁc MPR threshold values to achieve
more accurate estimation of adherence rates.
Overactive bladder/urinary incontinence patients
who discontinue treatment prematurely are unable
to obtain the full beneﬁt of therapy. Discontinuing
beneﬁcial medication can incur preventable morbid-
ity and impose a considerable clinical and economic
burden on the health-care system [43]. Establishing
effective and efﬁcient intervention programs to
improve patient persistence and adherence has been
placed on the agenda of improving health outcomes
of treatment and patients’ quality of life. Patient
education is signiﬁcant to ensure maintenance of
therapy; however, better patient monitoring by phy-
sicians and pharmacists to identify potential non-
compliant populations is equally important. A
comprehensive approach will be required for care of
patients including monitoring of ﬁlled prescription,
patient and clinician education, and the manage-
ment of patient risk factor proﬁles.
Table 6 The effect of OAB medication discontinuation on UTI incidence for 6-month follow-up period
Odds ratio (OR) P-value 95% CI of OR
Age 0.98 0.42 0.97–0.98
Age squared 1.00 0.92 1.00–1.00
Male 0.78 0.10 0.58–1.05
Dual eligibility (Medicare + Medicaid) 0.59 <0.01 0.43–0.80
Any previous emergency room visit 1.65 <0.01 1.12–2.44
Any previous OAB-related outpatient visit 0.83 0.15 0.64–1.07
Any previous OAB diagosis 0.74 <0.01 0.53–1.04
Index drug: tolterodine* 0.76 0.02 0.60–0.96
Any previous antipsychotic use 0.70 0.05 0.49–1.00
Multiple drugs used (polypharmacy)† 1.24 0.15 0.92–1.69
Any previous UTI diagnosis‡ 5.70 <0.01 4.45–7.31
Any previous UTI drug use 1.36 0.11 0.93–1.99
CCI on index date 1.16 <0.01 1.09–1.24
Discontinuation of OAB drug therapy 1.37 0.03 1.03–1.84
*Reference index drug is oxybutynin.
†More than one kind of medication used in follow-up period.
‡UTI diagnosis in 30 days before OAB/UI diagnosis was considered to be a misdiagnosis of OAB/UI diagnosis and was excluded from this calculation.
CCI, Charlson Comorbidity Index not including age.
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